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Abstract  
Study rationale: Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory 
myopathy of childhood with an incidence of 1.9-3.2 per million. The aetiology of 
JDM is uncertain but may result from immune dysregulation triggered by 
environmental factors in genetically susceptible children. The demographic and 
clinical characteristics of JDM may thus differ by race and geographic regions. Few 
studies have described the characteristics of JDM patients from Africa. There is need 
for further studies for better understanding of the epidemiology, clinical 
characteristics and outcome of patients with JDM from the continent. 
Methods: We conducted a retrospective observational study to determine clinical 
characteristics and outcomes of patients satisfying the Bohan and Peter criteria for 
probable JDM seen between 2004-2013 in Red Cross, Groote Schuur and Tygerberg 
hospitals in Cape Town. Data was analyzed using R version 3.1.0 (2014-04-10).  
Results: Twenty five cases were identified: 16 female and 9 male. Thirteen (52%) of 
the cases were of indigenous African, eleven (44%) mixed and one (4%) European 
ancestry. The median ages at disease onset and diagnosis were 6.75 (range 2.0-9.7) 
and 7.9 (range 3.4-9.75) years respectively. Muscle weakness and characteristic 
cutaneous manifestations occurred in all the 25 patients while 24 had elevated 
muscle enzymes.  All the patients received corticosteroids, seventeen (73.9%) 
received methotrexate and four received rituximab. Eleven patients had calcinosis 
during the disease course [median follow up period of 50 (range 0.5-159) months]. 
The mortality was 2/25 (8%) while only 40% of the patients had clinically inactive 
disease by PRINTO criteria.  There was no difference in racial distribution (p-value 
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= 1), age at disease onset (p-value = 0.87) and disease duration prior to treatment 
initiation (p-value = 0.75) between patients who had clinically active and inactive 
disease.  
Discussion: The demographic characteristics of children with JDM were similar to 
that from most other regions of the world with female predominance and similar age 
at onset. The median delay in diagnosis (4 months) was not longer than that reported 
in most other studies. However, some children had prolonged delay of up to 7 years 
due to misdiagnosis that denied them appropriate treatment in a timely manner. 
Majority (60%) of the patients also remained with clinically active disease, which put 
them at risk of further disease complications including calcinosis. Even though the 
mortality rate was low (8%) this was still more than double that reported in most 
recent large studies especially from the resource rich countries.  
Conclusions: Long term follow up of JDM patients is advisable since majority of 
patients seem to have clinically active disease many years after disease onset despite 
treatment. Formulation and use of appropriate treatment guidelines and protocols 
may aid in the early diagnosis and appropriate management for optimum outcomes.  
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1 Chapter 1: Introduction 
1.1 Context 
1.1.1 Historical perspective  
Juvenile dermatomyositis (JDM) is an immune mediated vasculopathic disease of 
childhood characterized by inflammation of the striated muscles, skin and internal 
organs. The descriptions of patients presenting with muscle damage and skin lesions 
were first given by Wagner in 1863[1]. Hans Unverritch later described a case of a 
man who presented with systemic symptoms, muscle weakness, periorbital 
discolorations and degenerative muscle changes on histology. This patient later died 
of respiratory failure. In 1891, Unverritch reported a second case and used for the 
first time, the term dermatomyositis to describe these cases.  
1.1.2 Aetiopathogenesis of juvenile dermatomyositis 
JDM probably arises as a result of immune dysregulation in genetically susceptible 
individuals following exposure to some as yet incompletely described environmental 
triggers. The role of genetic factors in the aetiology and pathogenesis of JDM has 
been backed by reports of familial clustering of JDM with other autoimmune 
diseases such as SLE, rheumatoid arthritis and type-1 Diabetes [2].  
Several HLA haplotypes such as HLA DRB1*0301, DQA1*0301, HLA-
DQA1*0501 and HLA-B8 occur more frequently in patients with JDM than in the 
general population and may thus confer risk for JDM. Conversely, HLA 
DQA1*0201 and DQA1*0101 alleles have been associated with lower risk of JDM 
in Caucasians [3,4]. Other gene loci that appear to confer risk of JDM include genes 
for the inflammatory cytokines TNFα, IL-1α and IL-1β; as well as the lymphocyte 
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signaling gene PTPN22. The TNF308A and IL1 polymorphisms are associated with 
higher risk of ulcerative disease and calcifications in JDM patients [4,5]. 
Environmental exposures such as infections, exposure to sunlight, vaccination and 
drugs have been reported as possible triggers [5-7] that may induce or worsen 
symptoms of JDM.  Seasonal clustering of cases of JDM has further added to the 
speculation about the role of infections in the pathogenesis of JDM [8].  
JDM is associated with a broad range of immune aberrations involving autoantibody 
production; complement mediated endothelial damage; aberrations in innate 
immunity and T-cell dysfunction. Increased levels of inflammatory cytokines 
including type I interferon stimulate up-regulation of MHC I expression on muscle. 
Expression of MHC I in myofibrils is associated with development of myositis with 
perivascular inflammatory cell (T cells, B cells, Macrophages and plasmacytoid 
dendritic cell) infiltration of muscle fibres [6]. 
Autoantibodies are identifiable in most cases of JDM.  These can be classified either 
as myositis specific antibodies (MSA) or myositis associated antibodies (MAA). The 
MAA also occur in autoimmune diseases other than JDM. The MSAs include: anti 
Jo-1, anti-SRP and anti-Mi2. The more recently described MSAs such as anti-TIF1 
(anti p155/140) and anti-NXP (anti p140) are more prevalent in JDM than the 
previously described autoantibodies and occur in upto 40% of JDM patients [4,9]. 
These newer MSAs are also associated with specific disease phenotypes with anti-
p140 being associated with calcinosis.   
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1.1.3 Demographic characteristics 
Dermatomyositis affects people of all ages though two peaks at onset have been 
described: 5-14 years and 45-64 years. The bimodal distribution demonstrates the 
uniqueness of the childhood [Juvenile Dermatomyositis (JDM)] form as a distinct 
disease from the adult form. JDM is the most common of the idiopathic 
inflammatory myopathies of childhood with incidence of 1.9-3.2 per a million [8,10]. 
Data from large patient registries indicate that the average age of onset of JDM is 
seven years (ranges from 5.7-8.7 years) with greater incidence in girls than boys 
(ratio of 1.9-4.2:1)[ 11-14]. However, regional differences exist and studies from 
India and Saudi Arabia have reported higher incidence rates in male children [15,16]. 
JDM occurs in all regions of the world though some studies suggest that there could 
be differences in incidence rates among different racial groups. Mendez et al found a 
lower incidence rate among children of Hispanic ancestry compared to those of 
African and Caucasian ancestry in the USA [10]. Racial differences have been noted 
in the incidence rates of certain disease manifestations with much higher incidence of 
calcinosis among children of African ancestry compared to other racial groups 
[12,17,18].  
1.1.4 Clinical characteristics, investigations and diagnosis 
JDM is a multisystem disease and manifests with symptoms in the skin, muscles as 
well as other organs including the lungs, gut, joints, heart and kidneys. Even though 
there are no validated criteria for the diagnosis and classification of JDM, the Bohan 
and Peter criteria which were initially proposed in 1975 for the diagnosis of 
inflammatory myositis in adults [19,20] are often applied for this purpose. The 
Bohan and Peter criteria are a set of five clinical and laboratory features that include 
characteristic cutaneous features, proximal muscle weakness, raised muscle enzymes, 
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characteristic muscle biopsy and suggestive electromyographic (EMG) findings. 
Presence of the characteristic cutaneous features with three of the other four criteria 
is necessary for a diagnosis of definite JDM while presence of the characteristic rash 
with two other features denotes Probable JDM.  
However, in current paediatric practice, muscle biopsy and EMG are rarely 
performed due to their invasive nature. Instead, Magnetic Resonance Imaging (MRI) 
of muscle has gained popularity and has been proposed as a non-invasive alternative 
to muscle biopsy and EMG for assessing muscle inflammation [21,22]. Further, 
whole body muscle MRI has been found to perform well in identifying areas of 
muscle inflammation, identifying areas of active inflammation to biopsy and in 
quantifying the inflammatory burden in JDM [23]. 
Other non-invasive modalities for the evaluation of muscle inflammation for 
diagnosing dermatomyositis that have been explored include PET scans [24,25], 
Ultrasound Scan (MSUS)[ 26,27], and Scintigraphy (bone scans) [ 28-30]. Even 
though MRI is increasingly being used in the diagnosis and monitoring of JDM, it is 
still relatively expensive and inaccessible in most resource limited settings like Sub-
Saharan Africa. Ultrasound is cheaper and more widely available compared to MRI. 
Further, MSUS is not associated with exposure to radiation just like with MRI. Bone 
scans are another alternative that is cheaper than MRI and may be less affected by 
operator (subjective) factors compared to MSUS. 
1.1.5 Management   
Steroids have been used empirically as the mainstay and first line of management of 
JDM even though there had been no Randomized Controlled Trials (RCTs) 
supporting their use and efficacy until recently. A multinational prospective cohort 
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study on the treatment modalities employed by clinicians confirmed steroids as being 
the most common drugs used in JDM treatment [33]. In addition to steroids, 
immunosuppressive and immune modulating drugs such as methotrexate, 
intravenous immunoglobulin (IVIG), azathioprine, cyclosporine, mycophenolate 
mofetil and cyclophosphamide have traditionally been used to induce remission in 
severe disease and as steroid sparing agents.  
In response to the lack of evidence based standardized guidelines, the Childhood 
Arthritis & Rheumatology Research Alliance (CARRA) proposed consensus 
treatment guidelines for the management of moderately severe JDM [31,32]. Three 
consensus treatment guidelines were proposed: Prednisone and methotrexate, 
Prednisone with methotrexate and pulse methyl prednisone; and Prednisone, 
methotrexate, pulse methyl prednisone and Intravenous Immunoglobulin. Ruperto et 
al [33] recently published the results of their RCT which showed that combination of 
prednisone with methotrexate or with cyclosporine was more effective than 
prednisone alone in the management of JDM. Further, the prednisone methotrexate 
combination had less adverse effects than the prednisone cyclosporine combination.  
Few studies have looked at the efficacy of biological agents in JDM and therefore 
there are currently insufficient data to recommend use of biologic agents for the 
treatment of JDM. Oddis et al conducted an RCT on the efficacy of rituximab in 
refractory adult and Juvenile Dermatomyositis and noted that rituximab was 
efficacious in management of refractory JDM to achieve the IMACS definition of 
improvement [34]. A small study looking at the efficacy of infliximab for the 
treatment of refractory JDM in 5 patients demonstrated clinical benefit in muscle 
strength, patient global wellbeing, physician global assessment of improvement and 
even calcinosis in all the patients [35]. However, some studies have reported 
 
Page 17 of 97 
 
unfavourable results with use of anti-TNF biologics in dermatomyositis and 
inflammatory myositis [36]. Generally, caution is advised in the use of anti-TNF 
biologics due to reports of TNF inhibitor induced dermatomyositis in patients 
receiving adalimumab and eternacept for the treatment of arthritis [37,38]. 
1.1.6 Treatment Outcome 
The outcome of JDM has markedly improved over the years. In the years before the 
introduction of steroids for the treatment of JDM (before 1960s), the mortality rates 
were about 30% and a further 30% of the patients survived with major sequelae [14]. 
With the use of modern diagnostic and therapeutic strategies, JDM mortality rate has 
reduced to less than 5% [14,39-41]. Despite the improvement in mortality rates 
among JDM patients, disease and treatment related damage such as calcinosis, 
interstitial lung disease, residual muscle weakness, lipodystrophy and steroid toxicity 
remain major challenges and significantly affect the quality of life of affected 
individuals.  
However, data on the characteristics and treatment outcome of JDM patients from 
Africa is scarce and only one study has been published that specifically described a 
series of JDM patients from the continent [12]. In that study, a higher rate of 
calcinosis and vasculitis compared to that from other regions was reported suggesting 
that the clinical manifestations and outcome of JDM in African patients could be 
different. There is need of further studies for a better understanding of the 
epidemiology, clinical manifestations and treatment outcomes of JDM in patients 
from Africa. We therefore carried out a study to review and describe the clinical 
features and treatment outcomes of JDM patients from Cape Town, South Africa.  
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1.2 Ethical considerations 
The study was approved by the Human Research Ethics Committees (HREC) of the 
Universities of Cape Town (HREC/REF: 062/2014, appendix 5) and Stellenbosch 
(Ref: S14/04/080, appendix 6). Permission to carry out the study and access patient 
records was sought from the respective hospital administrators. Consent from 
patients or their parents was not obtained since this was a retrospective case note 
review and did not involve direct patient contact. Patient confidentiality was 
observed and information collected was kept anonymous. The study was conducted 
in observance of the principles of Helsinki (2008) and Good Clinical Practice (GCP). 
1.3 Author guidelines Paediatric rheumatology journal  
The manuscript will be submitted to the journal Paediatric Rheumatology for 
publication. Paediatric Rheumatology is the official journal of the Paediatric 
Rheumatology European Society (PReS) and the premier journal specifically 
dedicated to paediatric rheumatology. It is an online open access journal and thus 
shall provide the maximum reach among the paediatric rheumatology community 
and to any other interested scientist, clinician or researcher. The journal does not 
limit the length of the manuscripts submitted for publication though authors are 
encouraged to be concise. The journal is listed in the citation index of the Institute 
for Scientific Information (ISI) and is accredited by the South African Department of 
Education.   
The full author guidelines for paediatric rheumatology journal is included as 
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2.1  Abstract  
Background: Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory 
myopathy of childhood with an incidence of 1.9-3.2 per million. The aetiology of 
JDM is uncertain but may result from immune dysregulation triggered by 
environmental factors in genetically susceptible children. The demographic and 
clinical characteristics of JDM may thus differ by race and geographic regions. Few 
studies have described the characteristics of JDM patients from Africa. There is need 
for further studies for better understanding of the epidemiology, clinical 
characteristics and outcome of patients with JDM from the continent. 
Methods: We conducted a retrospective observational study to determine clinical 
characteristics and outcomes of patients satisfying the Bohan and Peter criteria for 
probable JDM seen between 2004-2013 in Red Cross, Groote Schuur and Tygerberg 
hospitals in Cape Town. Data was analyzed using R version 3.1.0 (2014-04-10].  
Results: Twenty five cases were identified: 16 female and 9 male. Thirteen (52%) of 
the cases were of indigenous African, eleven (44%) mixed and one (4%) European 
ancestry. The median ages at disease onset and diagnosis were 6.75 (range 2.0-9.7) 
and 7.9 (range 3.4-9.75) years respectively. Muscle weakness and characteristic 
cutaneous manifestations occurred in all the 25 patients while 24 had elevated 
muscle enzymes.  All the patients received corticosteroids, seventeen (73.9%) 
received methotrexate and four received rituximab. Eleven patients had calcinosis 
during the disease course [median follow up period of 50 (range 0.5-159) months]. 
The mortality was 2/25 (8%) while only 40% of the patients had clinically inactive 
disease by PRINTO criteria.  There was no difference in racial distribution (p-value 
= 1), age at disease onset (p-value = 0.87) and disease duration prior to treatment 
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initiation (p-value = 0.75) between patients who had clinically active and inactive 
disease.  
Conclusion: The demographic characteristics of children with JDM were similar to 
that from most other regions of the world with female predominance and similar age 
at onset. However, majority of the patients remained with clinically active disease, 
which put them at risk of further disease complications including calcinosis. Long 
term follow up of JDM patients and use of appropriate treatment guidelines and 
protocols may guide appropriate management for optimum outcomes.  
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2.2 Background 
Juvenile dermatomyositis (JDM) is an immune mediated vasculopathic disease of 
childhood characterized by inflammation of the striated muscles, skin and internal 
organs. The most common clinical manifestations are proximal muscle weakness and 
characteristic cutaneous lesions such as heliotrope rash, Gottron’s papules and 
calcinosis. However, disease manifestations may occur in the lungs, heart, 
gastrointestinal tract and other organs. The pathogenesis of JDM is not fully 
understood but environmental factors are thought to trigger the disease in genetically 
predisposed children [1-4].  
JDM is most commonly diagnosed and classified using the Bohan and Peter criteria 
published in 1975 [5,6]. Though initially proposed for use in adults, these criteria are 
also widely used for diagnosis of myositis in the paediatric age group. The criteria 
include presence of a characteristic rash, symmetrical proximal muscle weakness, 
elevated muscle enzymes in serum, electromyographic changes and muscle biopsy 
features of inflammatory myositis. The presence of the skin manifestations is 
mandatory for diagnosis while presence of three of the other features is necessary for 
classification as definite JDM and of two other features as probable JDM. Presence 
of characteristic skin lesions without apparent muscle involvement may be seen in 
about 1.0% of cases and is referred to as amyopathic dermatomyositis [7]. 
Data from multicenter patient registries indicate that the average age of onset of JDM 
is seven years with greater incidence in girls than boys (ratio of 2:1) [8-11]. 
However, regional differences exist and studies from India and Saudi Arabia have 
reported higher incidence rates in male children [12,13]. JDM occurs in all regions of 
the world though some studies suggest that there could be differences in incidence 
rates among different racial groups. Mendez et al reported a lower incidence rate 
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among children of Hispanic ancestry compared to those of African and Caucasian 
ancestry in the USA [14]. Racial differences have also been noted in the incidence 
rates of certain disease manifestations with much higher incidence of calcinosis 
being reported among children of African ancestry compared to other racial groups 
[9,15,16].  
The reported treatment outcome of JDM has improved over the years. The mortality 
rate has significantly reduced from more than 30% before routine use of steroids 
[17], to less than 5% reported in most recent studies [11,18-20]. Despite the 
improvement in mortality rates among JDM patients, disease and treatment related 
damage remains a major challenge and significantly affect the quality of life of 
affected individuals. However, data on the characteristics and treatment outcome of 
JDM patients from Africa is scarce and only one study has been published that 
specifically described a series of JDM patients from the continent [9]. In that study, a 
higher rate of calcinosis and vasculitis compared to that from other regions was 
reported suggesting that the clinical manifestations and outcome of JDM in African 
patients could be different.  
There is need of further studies for a better understanding of the epidemiology and 
treatment outcomes of JDM in patients from Africa. We therefore carried out a study 
to review and describe the clinical features and treatment outcomes of patients seen 
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2.3 Methods 
2.3.1 Study design, study setting and patients  
We carried out a retrospective folder review of JDM patients seen between January 
2004 and December 2013 in three tertiary care hospitals [Tygerberg, Groote Schuur 
and Red Cross War Memorial Children’s Hospital) in Cape Town, South Africa. 
These three hospitals are the main tertiary referral hospitals for the Western Cape 
Province and also serve the surrounding regions of the Eastern and Northern Cape 
provinces of South Africa. Patients from this catchment area diagnosed with JDM 
were likely to have been referred to one of these centres for evaluation and treatment. 
The approximate population in the primary catchment area was 4.6 Million in 2004 
and 6.1 million in mid-2014 with children (people aged <15 years) constituting 35% 
and 26.5% of the population respectively [21]. The province populace is composed 
of people of diverse ancestral backgrounds with the most populous groups being, in 
descending order, people of mixed, indigenous African and European ancestries [21].   
Only patients who were seen between January 2004 and December 2013 and 
satisfied the Bohan and Peter criteria for classification as probable JDM were 
included. Data was extracted from the patient records as at the last review prior to 
31st December 2014 to allow for a follow up period of one year for each patient. Data 
was abstracted onto case record forms (CRF) and later transcribed onto an excel 
spreadsheet. Information collected included: demographics, clinical and laboratory 
features, radiological investigation results, treatment given and treatment outcomes. 
The primary outcome variable was disease activity at last review. Patients were 
classified as having clinically active disease or inactive disease. A modification of 
the PRINTO criteria for inactive disease [22] was used. The PRINTO criteria include 
CK<150 U/L, CMAS>48, MMT>78 and Physician global (VAS) <0.2. Patients 
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satisfying any three of these criteria are classified as having clinically inactive 
disease. We used a modification of these criteria due to difficulties with direct 
comparisons since this was a retrospective study and data on some of the PRINTO 
criteria items was not available. Therefore for this study we modified the criteria as 
follows (modification in brackets):   
• CK<150 U/L (No modification), 
• CMAS>48 (No modification), 
• MMT>78 (or documented full muscle strength using any muscle strength 
assessment scale by the attending physician) and 
• Physician global (VAS) <0.2 (or documentation of absence of symptoms and 
signs of active disease by the clinician). 
 Patients were classified as having inactive disease if they satisfied any three of these 
criteria.  
Secondary outcome measure was damage defined as persistent changes in anatomy, 
physiology or function present for at least 6 months at the last review (IMACS 
definitions of damage and specific damage items) [23,24]. Damage was assessed as 
being present or absent by systems and patients classified as either exhibiting 
damage (any) or none at last follow up. 
2.3.2 Data analysis 
Data was analysed using R i386 3.1.0 (The R Foundation for Statistical Computing, 
Vienna, Austria) software. Median and interquartile ranges were used for descriptive 
statistics for quantitative variables (non-normally distributed data). Frequencies were 
computed for qualitative variables. Non-parametric tests (Wilcoxon rank sum tests) 
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were used for comparison of medians across groups. For comparison between 
categorical variables, cross-tabulation was used with formulation of Fisher’s exact 
(chi square) statistic. The two sided p-values <0.05 were considered to be statistically 
significant.  
The study was approved by the human research ethics committees of Cape Town 
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2.4 Results   
2.4.1 Patient characteristics 
Twenty seven cases with a diagnosis of JDM seen between 2004 and 2013 were 
identified. Two had amyopathic JDM and were excluded as they did not meet the 
inclusion criteria of probable JDM. Of the other twenty five, twelve satisfied the 
criteria for definite JDM. Six of the probable JDM cases were reclassified as definite 
JDM when muscle MRI findings were considered. Thus in total, eighteen (72%) 
were classified as definite and seven (28%) probable JDM. Sixteen of the patients 
were female (F:M 1.8:1). Thirteen (52%) of the cases were of indigenous African, 
eleven (44%) mixed and one (4%) European ancestry. The median age at disease 
onset was 6.75 (range 2.0-9.7) years and at diagnosis 7.9 (range 3.4-9.75) years. The 
median duration from symptom onset to diagnosis was 4 (range 0.5-84) months. One 
patient was retrospectively diagnosed with JDM after a period of 84 months having 
previously been labelled as discoid lupus. The median duration of follow up was 50 
(range 0.5-159) months. Some of the findings are presented graphically in figure 1.  
 
Figure 1: Box and whisker plot illustrating delay in diagnosis (months). The median 
period from disease onset to diagnosis (delay) was 4 (range 0.5-84) months with 
maximum of 84 months for a patient initially diagnosed as discoid lupus before the 
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2.4.2 Diagnostic features and characteristics 
Muscle weakness and characteristic cutaneous manifestations were documented in all 
the 25 patients with heliotrope rash occurring in 20 and Gottron’s papules in 19 
patients. Muscle enzymes were elevated in all but one patient. This patient however, 
had suggestive muscle biopsy changes and satisfied the criteria for classification as 
probable JDM. Creatine phosphokinase (CK) was elevated in 22 of 24 cases. The 
two patients with normal CK had elevated AST and ALT and in addition one had 
elevated aldolase and the other had elevated lactose dehydrogenase (LDH). Aldolase 
was only determined in five patients and was elevated in three of them. Figure 2 
summarizes results of the diagnostic procedures and criteria. 
 
Figure 2:  Bar graph illustrating results of diagnostic investigations 
Present: features supportive of myositis; Absent: not supportive of myositis; Not 
available: Not done or results not accessible. Muscle enzymes were elevated in 24 of 
the 25 patients. Biopsy was done in 12 and showed features consistent with JDM in 
11. Other investigations done were EMG in 5 and MRI in 9 patients.  
 
Muscle biopsy was performed in twelve (48%) of the patients and showed 
characteristic features including perifascicular atrophy, fibre degeneration and 
regeneration and perivascular inflammation consistent with JDM in 11 (91.7%) of 
the cases. Figure 3 demonstrates some of the characteristic muscle biopsy changes of 
perifascicular atrophy (3a and b) and perivascular inflammation (3c and d) seen in 
one of our patients. Five of the patients had documented EMG results showing 
features consistent with myositis.  
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Figure 3a-d clockwise from top. Haematoxyllin and Eosin sections showing (a & 
b) perifascicular fibre atrophy (b high power); and c & d perivascular inflammation 
(c high power). Note the atrophic myofibres at the periphery of the fascicles (a & b) 
and the abundant perivascular mononuclear inflammatory cell infiltrates (c & d). 
These features are typical of dermatomyositis with accompanying vasculitis. 
 
Muscle MRI for initial diagnostic work-up was done in nine patients and 
demonstrated active inflammation in eight of the patients. Figure 4 shows the 
characteristic diffuse edema on MRI of the thigh muscles of one of the patients. All 
the patients in whom MRI was done were diagnosed in the latter half of the period 
under review (2009-2013).  
 
Figure 4: Saggital (STIR) and Coronal MRI images showing diffuse edema in the 
thigh muscles characteristic of JDM. 
 
 
2.4.3 Clinical characteristics 
There was no documented family history of neuromuscular or autoimmune diseases 
among the cases. However, history of preceding infection was reported in 6 cases: 
upper respiratory tract infection (URTI) in 4 cases and dental or skin abscesses in 2 
cases with a median time to onset of JDM symptoms of 1 month. One patient had a 
traumatic event (sexual abuse) one month prior to onset of JDM symptoms.  
Pulmonary involvement was reported in four patients and two of them died; one with 
suspected severe interstitial lung disease and the other with pulmonary hemorrhage 
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and sepsis. The third patient had clinical as well as HRCT features of interstitial lung 
disease (ILD) and restrictive pattern on pulmonary function tests (PFTs). One other 
patient had deranged spirometry results, which normalized with treatment. In total, 
PFT results were available for six patients (done after mean of 4.4 years from 
diagnosis) and only two of the patients had deranged lung function parameters 
(restrictive pattern).  
Cardiovascular involvement was observed in one patient who presented with 
generalized oedema and heart failure. Echocardiography showed mildly dilated 
chambers with reduced ejection fractions of <55%. Echocardiography however, was 
not routinely done to document baseline state or monitor cardiac function of JDM 
patients in the three centres. Neurological manifestations were seen in two cases; one 
had convulsions thought to be due to cerebral vasculitis and the other had localized 
sensory neuropathy.  
Cutaneous and musculoskeletal manifestations were the most common and are 
summarized together with other clinical features in Table 1. Of note, three patients 
had calcinosis at diagnosis, 8 others developed calcinosis and three had resolution of 
calcinosis during follow up. Figure 5 shows a radiograph of one of the patients 
showing tumoural and planar calcinosis in the forearm. There was no statistically 
significant difference in the age at onset, age at diagnosis and duration of follow up 
among patients who developed calcinosis and those who did not have calcinosis. The 
median time to diagnosis from symptom onset was longer in children who had 
calcinosis (6 months) than in those who did not have calcinosis (3 months). The 
difference was however not statistically significant (p = 0.13). In addition, even 
though there was a tendency towards a higher prevalence of calcinosis among 
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indigenous African children (8/13) compared to children of other racial backgrounds 
(3/12), the difference was not statistically significant (p=0.11).  
 
Figure 5: Forearm radiograph showing mixed tumoural and planar calcinosis in one 
of the JDM patients. 
 
2.4.4 Laboratory investigations 
 Autoantibodies [Myositis associated (MAA) and myositis specific antibodies 
(MSA)] were only tested in a few patients. Among the MSAs, only anti-Jo1 was 
tested and was negative in all the six patients tested. ANA results were available in 
19 patients and was low positive in seven (three had Hep-2 titres of 40, 40 and 100; 
and four had composite ANA ratio of 8, 2.2 4.6 and 32 U/L). The results of the 
laboratory investigations are summarized in table 2. 
2.4.5 Treatment 
Information on treatment was available for 23 of the 25 patients. We could not locate 
treatment records in two cases. The most common drugs used were oral prednisone 
(100%), methotrexate (74%), intravenous methylprednisolone (39%) and intravenous 
immunoglobulin (IVIG). Prednisone alone was used in five patients, prednisone and 
methotrexate without another agent in nine patients and various other drugs were 
added as second line drugs to the main treatment modality (prednisone and 
methotrexate) in poor responders as summarized in figure 6 below.  
 
Figure 6: Treatment modalities in Cape Town JDM patients. All the patients 
received corticosteroids during the course of their treatment.  Biologics were used in 
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6 patients (rituximab in 5 and infliximab in 1). Abbreviations:- Cyclophos: 
cyclophosphamide; Medrol: intravenous methylprednisolone; Pred: Prednisone 
PredMTX: Prednisone and methotrexate; IVIG: Intravenous immunoglobulin.  
 
 
2.4.6 Treatment outcome: diseases activity, mortality and damage 
Of the 25 patients, 10 were still in care, 8 were discharged, 2 transferred to other 
centres, 3 were lost to follow up and 2 patients died. Ten (40%) of the patients had 
clinically inactive disease. Patients who had clinically inactive disease had 
significantly lower CK levels (mean 105.5 U/L) than those with clinically active 
disease at their last review (mean CK 203.5 U/L) (p=0.02). There was no statistically 
significant difference in the median duration of follow up (p = 0.28), age of onset, 
race, diagnostic delay, disease category (probable or definite) and disease type 
(chronic/polycyclic or monocyclic) between those who had clinically inactive and 
active disease.  
The mortality rate was 2/25 (8%) over a median follow-up period of 50 months. 
Death resulted from respiratory failure in the setting of global weakness (and 
possible interstitial lung disease) in one patient and from sepsis, GI bleed and 
pulmonary hemorrhage (at autopsy) in the other. 
Overall, 18 (72%) of the patients had some documented damage though a full 
damage assessment was hampered by missing data occasioned by the retrospective 
nature of the study. The most common systems in which disease damage was 
reported were: endocrine (9 cases), skin (8 cases), musculoskeletal (7 cases) and 
respiratory (3 cases) systems. Endocrine damage was mainly as a result of growth 
failure (figure 7) though one patient developed diabetes mellitus and another, 
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adrenal insufficiency. Growth failure occurred in a high proportion of patients (36%). 
Growth failure was defined by the IMACS criteria as presence of two of the 
following three features: 
a. Less than 3 percentile height for age. 
b. Growth velocity over 6 months less than 3 percentile for age. 
c. Crossing at least 2 centiles (5%, 10%, 25%, 50%, 75%, 95%) on growth chart. 
 
Musculoskeletal damage included one patient who had osteoporosis with vertebral 
fracture that was demonstrated using bone scans (scintigraphy). One patient, who had 
suffered from suppurative otitis media during follow up, developed sensorineural 
hearing loss. Three patients had calcinosis at diagnosis, 8 developed calcinosis and 
three had resolution of the calcinosis during follow up.  
 
Figure 7: growth chart for one of the patients with growth failure. Note stature for 
age line crosses from above 50th centile to below 3rd centile and remains below 3rd  
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2.5 Discussion 
A better understanding of the epidemiology and clinical outcomes of JDM has been 
enhanced by the establishment of multicenter and multinational collaborations such 
as the paediatric rheumatology international trials organization (PRINTO) and 
international myositis assessment and clinical studies group (IMACS). However, 
data from Africa has been scarce and the epidemiology of JDM from the continent 
has been based on extrapolation of data collected from other populations and regions. 
The mean age at disease onset in most of these registries has been reported to be 
about seven years with a female predominance of about 2:1 [10,11,20]. The median 
age of onset (6.75 years) and gender composition (female: male 1.9:1) among the 
JDM patients in our series was similar to that of most studies from other regions.  
In the current study, we also found a relatively high rate of calcinosis (44% of the 
cases). Even though children of indigenous African ancestry appeared to have a 
higher prevalence of calcinosis (61.5%) compared to patients of other ancestral 
background (25%), the difference was not statistically significant (p=0.11). Higher 
rates of dystrophic calcinosis have been reported among indigenous African 
compared to JDM patients of other ancestral backgrounds [16].  It is not clear why 
indigenous African patients appear to have higher risk of calcinosis.  Certain immune 
phenotypes have been associated with higher risk of occurrence of calcinosis. It is 
not known if black African children have higher prevalence of these immune 
phenotypes thus putting them at greater risk for calcinosis. The immune phenotype 
was not determined for our patients and published studies are not available on the 
comparative prevalence of autoantibody and other associated risk factor profiles 
among indigenous African compared to children of other ancestral backgrounds. 
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Increased risk of calcinosis and other disease damage could also be related to poor 
access to care with subsequent inappropriate and delay in instituting treatment. Delay 
in diagnosis may be the consequence of lack of access to clinicians skilled in 
diagnosing and managing dermatomyositis and similar conditions; and lack of access 
to diagnostic facilities such as EMG and muscle biopsy. However, there was no 
significant difference in the delay in making a diagnosis between the patients of 
indigenous African and patients of other ancestral origins (p = 0.27).  
As the search for better and more acceptable diagnostic procedures and tools 
continues, MRI is gradually being used in the three centres instead of or in addition 
to EMG and muscle biopsy for diagnosis of JDM. Eleven muscle MRIs were done as 
part of the diagnostic evaluation of children; all in the latter half of the period under 
review. Thus MRI seems to have gained prominence as a diagnostic tool for JDM 
consistent with findings from other studies [19,25,26]. However, in Africa and many 
other resource constrained economies, MRI may not be available in many centres 
and even where it is available, long waiting times, technical issues with reporting and 
cost implications may prove prohibitive. Thus additional diagnostic modalities such 
as muscle ultrasound and Bone scintigraphy that may provide cheaper and more 
convenient alternatives for demonstrating evidence of muscle inflammation may be 
welcome [27-29].  
The mortality rate (8%, 1 death per 52 patient years) in our series appears higher than 
the 2-4% reported in most recent studies from other regions [11,18-20]. This finding 
was consistent with that by Faller et al [9] who reported a mortality of 9.5% (1 death 
per 27.3 patient years) among indigenous African children with JDM from 
Johannesburg, South Africa. These two studies were small and it’s not possible to 
draw generalizable conclusions. They however provide some insight into possible 
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treatment outcomes of JDM in Africa. Two deaths were reported in our study as well 
as in the study by Faller et al and all the four deaths resulted from respiratory 
(involvement) disease which has been identified as an early disease feature predictive 
of mortality [18].  
Juvenile dermatomyositis is a chronic disease and many patients may never achieve a 
clinically inactive disease state. After a median follow up time of 50 months, only 
ten (40 %) of the 25 patients had clinically inactive disease (PRINTO criteria) at 
their last follow up. Sanner et al studied the long-term outcome of JDM and after 
16.8 years, 59% of the patients still had clinically active disease [30]. Other authors 
have similarly reported a relatively high level of disease activity, with only 33% 
among a cohort of 39 JDM patients being disease free at last review over a ten year 
period [31]. It is thus clear that most children with JDM have long-term 
inflammation and disease activity that linger long after initiation of treatment. 
Formulation of appropriate guidelines and standard of care protocols to guide short-
term and long-term management of JDM could enable appropriate timely 
interventions for better treatment outcomes. 
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2.6 Conclusion 
The demographic characteristics of JDM patients from Cape Town (median disease 
onset age of 6.75 years and Female to male ration of 1.9:1) was similar to that 
reported from most regions of the world. It is probable that there was unnecessary 
delay in the diagnosis of cases. One patient was diagnosed retrospectively seven 
years after disease onset. There was however a relatively high rate of calcinosis 
(44%) and mortality (8%).  
Further, there was persistent clinically active disease in a large proportion of this 
cohort (60%), putting them at risk of further disease complications. This could be a 
reflection of inadequate or less aggressive treatment. The study adds to the available 
literature on JDM in Africa and demonstrates a need for a defined standard of care 
package to ensure adequate access to skilled multidisciplinary teams, essential 
diagnostic facilities and therapeutic resources for better treatment outcomes. 
 The study limitations included missing values and the relatively small number of 
cases identified. Establishment of a prospective cohort in future could be useful in 
providing better quality data for better outcome assessments in line with currently 
accepted international guidelines.  
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2.7 List of abbreviations 
AST Aspartate transaminase 
CMAS           Childhood Myositis Assessment Scale 
CRP C-Reactive Protein
CT Scan         Computerised Tomography Scan 
CK Creatine Kinase   
EMG              Electromyography  
ESR Erythrocyte Sedimentation Rate 
IMACS          International Myositis And Clinical Studies 
IVIG              Intra-Venous Immune Globulin  
JDM Juvenile Dermatomyositis   
LDH               Lactate Dehydrogenase 
MAA              Myositis Associated Antibodies 
MDI Myositis Damage Index  
MMT  Manual Muscle Testing 
MRI Magnetic Resonance Imaging  
MSA Myositis Specific Antibodies 
PRINTO         Paediatric Rheumatology International Trials Organization 
vWF Von Willebrand Factor 
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2.12 Tables and figures 








Skin 8 (32) 
Calcinosis, scarring, atrophy 11 (44) 8 (32) 
Skin ulcers 11 (44) 1 
Oedema (Generalized, Periorbital or limb) 11 (44) 0 
Alopecia 3 (12) 3 (12) 
Lipodystrophy 1 (4) 1 (4) 
Musculoskeletal 7(28) 7 (28) 
Muscle tenderness 13 (52) 0 
Arthritis 7 (28) 2 (8) 
Contractures 5(20) 5 (20) 
Muscle wasting 4 (16) 4 (16) 
Osteoporosis with fracture 1(4) 1 (4) 
Endocrine 9 (36) 9 (36) 
Growth failure 8 (32) 8 (32) 
Diabetes mellitus 1 (4) 1 (4) 
Adrenal insufficiency 1 (4) 1 (4) 
Respiratory 3 (12) 3 (12) 
Interstitial lung disease (ILD) 2 (8) 2 (8) 
Dysphonia 2 (8) 0 
Hemorrhagic pneumonitis  1 (4) 1 (4) 
Gastrointestinal 
 Dysphagia 5 (20) 0 
 Abdominal pain or bleeding 3 (12) 0 
Ocular 2 (8) 2 (8) 
Cataracts 2 (8 2 (8) 
Cardiovascular 
Abnormal capillaroscopy 15 (60) NA 
Raynaud’s phenomenon 6 (24) NA 
Cardiomyopathy 1 (4) 0 
Nervous system   
Seizures; neuropathy 2 (8) 0 
Sensorineural hearing loss 1 (4) 1 (4) 
Infections 
Fungal (skin) 7 (28) NA 
Bacterial (staph aureus 2, gram neg 1) 3 (12) NA 
TB 2 (8) NA 
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Table 2: Laboratory investigation results 




CK 26 - 145 U/L 1074.0 (222.8-3397.5) 22/24 91.7 
Aldolase 3.0 - 12.0U/L 12.6 (7.7-15.9) 3/5 60 
LDH 142 - 261U/L 445.0 (277.0- 493.5) 14/19 73.7 
AST 0 - 41 U/L 74.0  (35.25-140.5) 16/22 72.7 
ALT 5 - 25 U/L 48.0 (26.5-82.0) 18/23 78.3 
Autoantibody 
Anti-Jo1 <7 EliA U/ml 0.3 (0.3 - 0.45) 0/6 0 
Anti-p155/140 NA NA 0 0 
Anti-p140 NA NA 0 0 
Anti-RNP <7 EliA U/ml 0.3 (0.3 - 0.5) 0/9 0 
Inflammatory markers 
ESR 20 (12 - 35) 11/19 57.9 
CRP 2.6 (<1- 6) 2/10 20 
vWF activity 77 (62-112%) 2/4 50 
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Number  10 15 
Sex (F/M) 8/2 8/7 p =  0.228‡ 
Race (Indigenous African/other) 5/5 8/7 P = 1 
Age at onset (Median) years 7.8 6.0 p = 0.868‡ 
Time to diagnosis (Median) 
months 
3.5 4.5 p = 0.745‡ 
Duration follow up (Median) 
months 
55.5 49.1 p = 0.21‡ 
Calcinosis    (Yes/No) 4/6 6/9 p = 1† 
CK (Median) 105.5 203.5 W = 109, p = 0.02‡ 
Disease type: Chronic/poly- vs 
Mono 
p =  0.35† 
†Fisher exact       ‡ Wilcoxon rank sum test      
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Figure 1: Box and whisker plot illustrating age of patients (years) and delay in 
diagnosis (months). The median age at onset was 6.75 years and at diagnosis 7.9 
years. The median period from disease onset to diagnosis (delay) was 4 months with 
maximum of 84 months (the extreme outlier) for a patient initially diagnosed as 
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Figure 2:  Bar graph illustrating results of diagnostic investigations 
Present: features supportive of myositis; Absent: not supportive of myositis; Not
available: Not done or results not accessible. Muscle enzymes were elevated in 24 of 
the 25 patients. Biopsy was done in 12 and showed features consistent with JDM in 
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Figure 3a-3d clockwise from the top. Haematoxyllin and Eosin sections showing (a 
& b) perifascicular fibre atrophy (b high power); and c & d perivascular 
inflammation (c high power). Note the atrophic myofibres at the periphery of the 
fascicles (a & b) and the abundant perivascular mononuclear inflammatory cell 
infiltrates (c & d). These features are typical of dermatomyositis with the 
accompanying vasculitis. 
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Figure 4: Saggital (STIR) and Coronal MRI images showing diffuse edema in the 
thigh muscles characteristic of JDM. 
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Figure 5: Forearm radiograph showing mixed tumoural and planar calcinosis in one 
of the JDM patients. 
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Figure 6: Treatment modalities in Cape Town JDM patients. All the patients 
received corticosteroids during the course of their treatment.  Biologics were used in 
6 patients (rituximab in 5 and infliximab in 1).  
Abbreviations. Cyclophos: cyclophosphamide; Medrol: intravenous 
methylprednisolone; Pred: Prednisone PredMTX: Prednisone and methotrexate; 
IVIG: Intravenous immunoglobulin.  
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Figure 7: growth chart for one of the patients with growth failure. Note stature for 
age line crosses from above 50th centile to below 3rd centile and remains below 3rd 
centile line for >3 years.  
Graph  produced by replotting the child growth indices on the WHO AnthroPlus 
v1.0.4 software (http://www.who.int/growthref/tools/en/).  
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2.13 Appendices  
2.13.1 Appendix 1: Case record form 
Section A: Demographic data and disease classification 
Sex 1. Male 2.    Female 
Birth Date 
Race 1. Indigenous African 2. European Caucasian 
3. Cape coloured 4. Other 
Residential address Province/Municipality….…………………………….. 
Date of onset Date of first visit Date of diagnosis 
Outcome: 1. Ongoing care 2. Discharged
3. Lost to follow up 4. Death
Last Date of Visit 
Family history of autoimmune disease 
(1= Yes; 2= No; 3=Unknown)  
If Yes, Specify disease and relationship 
Diagnostic criteria    0 = Not present  1 = Present  NA = Cannot be assessed 
1. Heliotrope rash OR Gottron’s papules/sign
2. Proximal Muscle Weakness
3. Muscle Biopsy Changes
4. Electromyographic changes
5. Muscle MRI changes
6. Elevated Muscle Enzymes
Classification (1. Definite JDM; 2. Probable 
JDM; 3. Amyopathic  4. Mixed Connective 
Tissue Disease 5. Does not satisfy criteria for 
probable JDM) 
Comorbid conditions (specify) 
Section B: Clinical manifestations 
A modified Myositis Disease Activity Assessment Tool (MDAAT) shall be used to 
document the clinical features that were present at diagnosis (or first visit) and 
cumulatively upto the last documented visit. 
Constitutional Activity NA = Cannot be assessed 0 = Not present 1 = Present 
At diagnosis Cumulatively 
Pyrexia (fever > 38○ Celsius) 
Weight loss 
Fatigue, malaise, lethargy 
Cutaneous Activity NA = Can’t be assessed 0 = Not present 1 = Present 
At diagnosis Cumulatively 
Cutaneous ulceration 





Nailfold capillary changes 
Alopecia, diffuse hair loss 
Alopecia, patchy 
Mechanics hands 
Skeletal Disease Activity  NA = Can’t be assessed 0 = Not present  1 = 
Present 




Gastrointestinal Disease Activity 
At diagnosis Cumulatively 
Dysphagia 
Moderate/severe abdominal  
pain 
Mild abdominal pain 
Pulmonary Disease Activity     
At diagnosis Cumulatively 
Dyspnoea 
Dysphonia 
Cardiovascular Disease Activity 









Other disease activity 
25.  Relapses
Manifestation Time from 
remission 
Cause Action 
26.  Disease activity core set measures:
Core set Diagnosis Review 1 Review 2 Other reviews 
CMAS 
MMT8 
VAS Physician  
VAS Patient global 
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CHAQ 
Section C: Drugs and other therapeutic modalities 
At diagnosis during disease 
Dose and Duration Dose and Duration 
1. Prednisone (Medrol I.V) 













Section D: Diagnostic work up 
Laboratory work up     
Reference 
range 
Value at assessment 
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Results of Radiological and other Diagnostic investigations 
Modality         Assessment 
First Second Third 
1. Muscle MRI 
2. Chest CT 
3. Barium swallow 
4. Muscle biopsy 
5. EMG 
6. Spectroscopy 







Section E: Damage Assessment 
A modified Myositis Damage Index (MDI) tool shall be used to document organ 
damage cumulatively over the entire period of care till the last documented visit. The 
items are scored as present (1), absent (0) or Cannot be assessed (NA).  
MUSCLE DAMAGE    NA = Cannot be assessed     0 = Not present    1 = Present 
1. Muscle atrophy (clinical)     0 1 NA 
2. Muscle weakness not attributable to active muscle disease   0  1 NA 
3. Muscle dysfunction: decrease in aerobic exercise capacity   0 1 NA 
4. Muscle atrophy assessed by radiographic methods     0 1 NA 
5. Low serum creatinine (Value…………………..)      0 1 NA 
SKELETAL DAMAGE  NA = Cannot be assessed   0 = Not present  1 = Present 
6. Joint contractures 0 1 NA 
7. Osteoporosis with fracture / vertebral collapse 0 1 NA 
8. Avascular necrosis 0 1 NA 
9. Deforming arthropathy (excluding contractures) 0 1 NA 
10. Osteoporosis without clinical fracture, 0 1 NA 
11. Limitation of motion (Passive Joint ROM in degrees):
a. Elbow extension (degrees):  R______L_______ 0 1 NA 
b. Hip flexion (degrees):   R______L_______ 0 1 NA 
c. Knee extension (degrees): R______L_______ 0 1 NA 
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d. Ankle dorsiflesion (degrees)  R______L_______ 0 1 NA 
CUTANEOUS DAMAGE NA = Cannot be assessed  0 = Not present  1 = Present 
12. Calcinosis: 0 1 NA 
a. Calcinosis, superficial plaques or nodules 0 1 NA 
b. Calcinosis, tumoral 0 1 NA 
c. Calcinosis, planar 0 1 NA 
d. Calcinosis, exoskeleton/calcinosis universalis 0 1 NA 
13. Alopecia 0 1 NA 
14. Cutaneous scarring or atrophy 0 1 NA 
15. Poikiloderma 0 1 NA 
16. Lipodystrophy 0 1 NA 
GASTROINTESTINAL (GI) DAMAGE    
17. Dysphagia   0        1          NA 
18. GI dysmotility, constipation, diarrhea or abdominal pain  0          1          NA 
19. Infarction or resection of bowel or other GI  0 1 NA   
20. Steatosis          0 1 NA 
PULMONARY DAMAGE NA = Cannot be assessed  0 = Not present 1= Present 
21. Dysphonia    0 1 NA 
22. Impaired lung function due to respiratory muscle damage 0 1 NA 
23. Pulmonary fibrosis    0 1 NA 
24. Pulmonary hypertension    0 1 NA 
25. Diminished lung function:
a. DL-CO/Va (Carbon monoxide diffusing capacity corrected for alveolar volume)
(% Predicted =_____________%)    0 1 NA 
b. FEV1 (% predicted =_________%)  0 1       NA 
CARDIOVASCULAR DAMAGE NA=Can’t be assessed 0=Not present 1=Present 
26. Hypertension requiring treatment > 6 months 0 1 NA 
27. Ventricular dysfunction / cardiomyopathy 0 1 NA 
PERIPHERAL VASCULAR DAMAGE 
30. Tissue or pulp loss 0 1 NA 
31. Digit or limb loss or resection 0 1 NA 
32. Venous or arterial thrombosis with swelling, ulceration or venous stasis
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0 1 NA 
ENDOCRINE DAMAGE  NA = Cannot be assessed  0 = Not present 1 = Present 
34. Growth failure   0 1 NA 
35. Delay in development of secondary sexual characteristics 0 1 NA 
36. Hirsutism or Hypertrichosis    0 1 NA 
37. Irregular menses    0 1 NA 
38. Primary or Secondary Amenorrhea    0 1 NA 
39. Diabetes    0 1 NA 
40. Hyperlipidemia (regardless of treatment)    0 1 NA 
41. Infertility (female or male)    0 1 NA 
42. Sexual dysfunction    0 1 NA 
OCULAR DAMAGE    NA = Cannot be assessed     0 = Not present  1 = Present 
43. Cataract resulting in visual loss 0 1 NA 
44. Visual loss, other, not secondary to cataracts 0 1 NA 
INFECTION     NA = Cannot be assessed 0 = Not present  1 = Present 
45. Chronic infections:________________________________0 1 NA 
46. Multiple infections Specify:_________________________0 1 NA 
 MALIGNANCY               NA = Cannot be assessed 0 = Not present  1 = Present 
47. Any form of cancer, Specify type, grade and stage:________0    1 NA
OTHER DAMAGE, specify NA = Cannot be assessed 0 = Not present 1 = 
Present 
48. Death: Cause and date__________________________ 0 1 NA 
49. Other (specify):____________________________________________________
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2.13.2 Appendix 2: Confidential log of JDM study patients. 
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2.13.3 Appendix 3: Budget 
The principal investigator shall do the data collection and analysis. 
The budget is self-funded. 
ITEM COST 
Telephone, cell phone & fax R – 100 
Internet & email R – 0 
Office supplies R – 100 
Courier & postage R – 200 
Printing & copying R – 200 
Ethics committee fee R – 0 
Transport R – 300 
Total direct costs R – 900 
Indirect costs (12%) R – 108 
GRAND TOTAL R–1008 
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2.13.4 Appendix 4: Timelines 




1. Proposal preparation October 2013 December 2013 
2. Proposal submission for review 
and ethical approval 
December 2013 April 2014 
3. Data collection April 2014 May 2014 
4. Dissertation write up October 2014 February 2015 
5. Dissertation submission March 2015. April 2015 
6. Submission of articles for 
publication 
April 2014 August 2014 
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2.13.5 Appendix 5: Ethics committee approval University of Cape Town 
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2.13.6 Appendix 6: Ethics committee approval University of Stellenbosch 
signature removed
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2.13.7 Appendix 7: Paediatric rheumatology Instructions for authors 
Downloaded from 
Presubmission enquiries: If you wish to make a presubmission enquiry about the 
suitability of your manuscript, please email the editors who will respond to your 
enquiry as soon as possible. 
Submission process: Manuscripts must be submitted by one of the authors of the 
manuscript, and should not be submitted by anyone on their behalf. The submitting 
author takes responsibility for the article during submission and peer review.  
Please note that Pediatric Rheumatology levies an article-processing charge on all 
accepted Research Articles; if the submitting author's institution is a BioMed Central 
member the cost of the article-processing charge may be covered by the membership 
(see About page for detail). Please note that the membership is only automatically 
recognised on submission if the submitting author is based at the member institution. 
To facilitate rapid publication and to minimize administrative costs, Pediatric 
Rheumatology prefers online submission. Files can be submitted as a batch, or one by 
one. The submission process can be interrupted at any time; when users return to the 
site, they can carry on where they left off.  
See below for examples of word processor and graphics file formats that can be 
accepted for the main manuscript document by the online submission system. 
Additional files of any type, such as movies, animations, or original data files, can 
also be submitted as part of the manuscript.  
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During submission you will be asked to provide a cover letter. Use this to explain 
why your manuscript should be published in the journal, to elaborate on any issues 
relating to our editorial policies in the 'About Pediatric Rheumatology' page, and to 
declare any potential competing interests. You will be also asked to provide the 
contact details (including email addresses) of potential peer reviewers for your 
manuscript. These should be experts in their field, who will be able to provide an 
objective assessment of the manuscript. Any suggested peer reviewers should not 
have published with any of the authors of the manuscript within the past five years, 
should not be current collaborators, and should not be members of the same research 
institution. Suggested reviewers will be considered alongside potential reviewers 
recommended by the Editor-in-Chief and/or Editorial Board members.  
Assistance with the process of manuscript preparation and submission is available 
from BioMed Central customer support team. We also provide a collection of links 
to useful tools and resources for scientific authors on our Useful Tools page. 
File formats 
The following word processor file formats are acceptable for the main manuscript 
document:  
 Microsoft word (DOC, DOCX)
 Rich text format (RTF)
 Portable document format (PDF)
 TeX/LaTeX (use BioMed Central's TeX template)
 DeVice Independent format (DVI)
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TeX/LaTeX users: Please use BioMed Central's TeX template and BibTeX stylefile 
if you use TeX format. During the TeX submission process, please submit your TeX 
file as the main manuscript file and your bib/bbl file as a dependent file. Please also 
convert your TeX file into a PDF and submit this PDF as an additional file with the 
name 'Reference PDF'. This PDF will be used by internal staff as a reference point to 
check the layout of the article as the author intended. Please also note that all figures 
must be coded at the end of the TeX file and not inline. 
If you have used another template for your manuscript, or if you do not wish to use 
BibTeX, then please submit your manuscript as a DVI file. We do not recommend 
converting to RTF. For all TeX submissions, all relevant editable source must be 
submitted during the submission process. Failing to submit these source files will 
cause unnecessary delays in the publication procedures. 
Preparing main manuscript text 
General guidelines of the journal's style and language are given below. 
Overview of manuscript sections for Research Articles 
Manuscripts for Research Articles submitted to Pediatric Rheumatology should be 
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 Results and discussion
 Conclusions







 Illustrations and figures (if any)
 Tables and captions
 Preparing additional files
The Accession Numbers of any nucleic acid sequences, protein sequences or atomic 
coordinates cited in the manuscript should be provided, in square brackets and 
include the corresponding database name; for example, [EMBL:AB026295, 
EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-
Prot:Q96KQ7, PIR:S66116]. 
The databases for which we can provide direct links are: EMBL Nucleotide 
Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the 
NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) 
and the Swiss-Prot Protein Database (Swiss-Prot). 
You can download a template (Mac and Windows compatible; Microsoft Word 
98/2000) for your article. 
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For reporting standards please see the information in the About section. 
Title page 
The title page should: 
 provide the title of the article
 list the full names, institutional addresses and email addresses for all authors
 indicate the corresponding author
Please note: 
 the title should include the study design, for example "A versus B in the
treatment of C: a randomized controlled trial X is a risk factor for Y: a case
control study"
 abbreviations within the title should be avoided
Abstract 
The Abstract of the manuscript should not exceed 350 words and must be structured 
into separate sections: Background, the context and purpose of the study; Methods, 
how the study was performed and statistical tests used; Results, the main findings; 
Conclusions, brief summary and potential implications. Please minimize the use of 
abbreviations and do not cite references in the abstract. Trial registration, if your 
research reports the results of a controlled health care intervention, please list your 
trial registry, along with the unique identifying number (e.g. Trial registration: 
Current Controlled Trials ISRCTN73824458). Please note that there should be no 
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space between the letters and numbers of your trial registration number. We 
recommend manuscripts that report randomized controlled trials follow the 
CONSORT extension for abstracts. 
Keywords 
Three to ten keywords representing the main content of the article. 
Background 
The Background section should be written in a way that is accessible to researchers 
without specialist knowledge in that area and must clearly state - and, if helpful, 
illustrate - the background to the research and its aims. Reports of clinical research 
should, where appropriate, include a summary of a search of the literature to indicate 
why this study was necessary and what it aimed to contribute to the field. The section 
should end with a brief statement of what is being reported in the article. 
Methods 
The methods section should include the design of the study, the setting, the type of 
participants or materials involved, a clear description of all interventions and 
comparisons, and the type of analysis used, including a power calculation if 
appropriate. Generic drug names should generally be used. When proprietary brands 
are used in research, include the brand names in parentheses in the Methods section. 
For studies involving human participants a statement detailing ethical approval and 
consent should be included in the methods section. For further details of the journal's 
editorial policies and ethical guidelines see 'About this journal'. 
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For further details of the journal's data-release policy, see the policy section in 'About 
this journal'. 
Results and discussion 
The Results and discussion may be combined into a single section or presented 
separately. Results of statistical analysis should include, where appropriate, relative 
and absolute risks or risk reductions, and confidence intervals. The Results and 
discussion sections may also be broken into subsections with short, informative 
headings. 
Conclusions 
This should state clearly the main conclusions of the research and give a clear 
explanation of their importance and relevance. Summary illustrations may be 
included. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, and 
a list of abbreviations can be provided, which should precede the competing interests 
and authors' contributions. 
Competing interests 
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A competing interest exists when your interpretation of data or presentation of 
information may be influenced by your personal or financial relationship with other 
people or organizations. Authors must disclose any financial competing interests; 
they should also reveal any non-financial competing interests that may cause them 
embarrassment were they to become public after the publication of the manuscript. 
Authors are required to complete a declaration of competing interests. All competing 
interests that are declared will be listed at the end of published articles. Where an 
author gives no competing interests, the listing will read 'The author(s) declare that 
they have no competing interests'. 
When completing your declaration, please consider the following questions: 
Financial competing interests 
 In the past three years have you received reimbursements, fees, funding, or
salary from an organization that may in any way gain or lose financially from
the publication of this manuscript, either now or in the future? Is such an
organization financing this manuscript (including the article-processing
charge)? If so, please specify.
 Do you hold any stocks or shares in an organization that may in any way gain
or lose financially from the publication of this manuscript, either now or in
the future? If so, please specify.
 Do you hold or are you currently applying for any patents relating to the
content of the manuscript? Have you received reimbursements, fees, funding,
or salary from an organization that holds or has applied for patents relating to
the content of the manuscript? If so, please specify.
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 Do you have any other financial competing interests? If so, please specify.
Non-financial competing interests 
Are there any non-financial competing interests (political, personal, religious, 
ideological, academic, intellectual, commercial or any other) to declare in relation to 
this manuscript? If so, please specify. 
If you are unsure as to whether you, or one your co-authors, has a competing interest 
please discuss it with the editorial office. 
Authors' contributions 
In order to give appropriate credit to each author of a paper, the individual 
contributions of authors to the manuscript should be specified in this section. 
According to ICMJE guidelines, An 'author' is generally considered to be someone 
who has made substantive intellectual contributions to a published study. To qualify 
as an author one should 1) have made substantial contributions to conception and 
design, or acquisition of data, or analysis and interpretation of data; 2) have been 
involved in drafting the manuscript or revising it critically for important intellectual 
content; 3) have given final approval of the version to be published; and 4) agree to 
be accountable for all aspects of the work in ensuring that questions related to the 
accuracy or integrity of any part of the work are appropriately investigated and 
resolved. Each author should have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content. Acquisition of funding, 
collection of data, or general supervision of the research group, alone, does not 
justify authorship.  
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We suggest the following kind of format (please use initials to refer to each author's 
contribution): AB carried out the molecular genetic studies, participated in the 
sequence alignment and drafted the manuscript. JY carried out the immunoassays. 
MT participated in the sequence alignment. ES participated in the design of the study 
and performed the statistical analysis. FG conceived of the study, and participated in 
its design and coordination and helped to draft the manuscript. All authors read and 
approved the final manuscript.  
All contributors who do not meet the criteria for authorship should be listed in an 
acknowledgements section. Examples of those who might be acknowledged include 
a person who provided purely technical help, writing assistance, or a department 
chair who provided only general support. 
Authors' information 
You may choose to use this section to include any relevant information about the 
author(s) that may aid the reader's interpretation of the article, and understand the 
standpoint of the author(s). This may include details about the authors' qualifications, 
current positions they hold at institutions or societies, or any other relevant 
background information. Please refer to authors using their initials. Note this section 
should not be used to describe any competing interests. 
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interpretation of data, or who was involved in drafting the manuscript or revising it 
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authorship. Please also include the source(s) of funding for each author, and for the 
manuscript preparation. Authors must describe the role of the funding body, if any, 
in design, in the collection, analysis, and interpretation of data; in the writing of the 
manuscript; and in the decision to submit the manuscript for publication. Please also 
acknowledge anyone who contributed materials essential for the study. If a language 
editor has made significant revision of the manuscript, we recommend that you 
acknowledge the editor by name, where possible.  
The role of a scientific (medical) writer must be included in the acknowledgements 
section, including their source(s) of funding. We suggest wording such as 'We thank 
Jane Doe who provided medical writing services on behalf of XYZ Pharmaceuticals 
Ltd.' 
Authors should obtain permission to acknowledge from all those mentioned in the 
Acknowledgements section. 
Endnotes 
Endnotes should be designated within the text using a superscript lowercase letter 
and all notes (along with their corresponding letter) should be included in the 
Endnotes section. Please format this section in a paragraph rather than a list. 
References 
All references, including URLs, must be numbered consecutively, in square brackets, 
in the order in which they are cited in the text, followed by any in tables or legends. 
Each reference must have an individual reference number. Please avoid excessive 
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referencing. If automatic numbering systems are used, the reference numbers must be 
finalized and the bibliography must be fully formatted before submission. 
Only articles, clinical trial registration records and abstracts that have been published 
or are in press, or are available through public e-print/preprint servers, may be cited; 
unpublished abstracts, unpublished data and personal communications should not be 
included in the reference list, but may be included in the text and referred to as 
"unpublished observations" or "personal communications" giving the names of the 
involved researchers. Obtaining permission to quote personal communications and 
unpublished data from the cited colleagues is the responsibility of the author. 
Footnotes are not allowed, but endnotes are permitted. Journal abbreviations follow 
Index Medicus/MEDLINE. Citations in the reference list should include all named 
authors, up to the first six before adding 'et al.'.. 
Any in press articles cited within the references and necessary for the reviewers' 
assessment of the manuscript should be made available if requested by the editorial 
office. An Endnote style file is available. 
Examples of the Pediatric Rheumatology reference style are shown below. Please 
ensure that the reference style is followed precisely; if the references are not in the 
correct style they may have to be retyped and carefully proofread.  
All web links and URLs, including links to the authors' own websites, should be 
given a reference number and included in the reference list rather than within the text 
of the manuscript. They should be provided in full, including both the title of the site 
and the URL, in the following format: The Mouse Tumor Biology Database 
[http://tumor.informatics.jax.org/mtbwi/index.do]. If an author or group of authors 
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can clearly be associated with a web link, such as for weblogs, then they should be 
included in the reference. 
Examples of the Pediatric Rheumatology reference style 
Article within a journal 
Smith JJ. The world of science. Am J Sci. 1999;36:234-5. 
Article within a journal (no page numbers) 
Rohrmann S, Overvad K, Bueno-de-Mesquita HB, Jakobsen MU, Egeberg R, 
Tjønneland A, et al. Meat consumption and mortality - results from the European 
Prospective Investigation into Cancer and Nutrition. BMC Medicine. 2013;11:63. 
Article within a journal by DOI 
Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. 
Dig J Mol Med. 2000; doi:10.1007/s801090000086. 
Article within a journal supplement 
Frumin AM, Nussbaum J, Esposito M. Functional asplenia: demonstration of splenic 
activity by bone marrow scan. Blood 1979;59 Suppl 1:26-32. 
Book chapter, or an article within a book 
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: 
Bourne GH, Danielli JF, Jeon KW, editors. International review of cytology. 
London: Academic; 1980. p. 251-306. 
OnlineFirst chapter in a series (without a volume designation but with a DOI) 
Saito Y, Hyuga H. Rate equation approaches to amplification of enantiomeric excess 
and chiral symmetry breaking. Top Curr Chem. 2007. doi:10.1007/128_2006_108. 
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Complete book, authored 
Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of 
common illness. 3rd ed. Oxford: Blackwell Science; 1998. 
Online document 
Doe J. Title of subordinate document. In: The dictionary of substances and their 
effects. Royal Society of Chemistry. 1999. http://www.rsc.org/dose/title of 
subordinate document. Accessed 15 Jan 1999. 
Online database 
Healthwise Knowledgebase. US Pharmacopeia, Rockville. 1998. 
http://www.healthwise.org. Accessed 21 Sept 1998. 
Supplementary material/private homepage 
Doe J. Title of supplementary material. 2000. http://www.privatehomepage.com. 
Accessed 22 Feb 2000. 
University site 
Doe, J: Title of preprint. http://www.uni-heidelberg.de/mydata.html (1999). 
Accessed 25 Dec 1999. 
FTP site 
Doe, J: Trivial HTTP, RFC2169. ftp://ftp.isi.edu/in-notes/rfc2169.txt (1999). 
Accessed 12 Nov 1999. 
Organization site 
ISSN International Centre: The ISSN register. http://www.issn.org (2006). Accessed 
20 Feb 2007. 
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Preparing illustrations and figures 
Illustrations should be provided as separate files, not embedded in the text file. Each 
figure should include a single illustration and should fit on a single page in portrait 
format. If a figure consists of separate parts, it is important that a single composite 
illustration file be submitted which contains all parts of the figure. There is no charge 
for the use of color figures. 
Please read our figure preparation guidelines for detailed instructions on maximising 
the quality of your figures. 
Formats 
The following file formats can be accepted: 
 PDF (preferred format for diagrams)
 DOCX/DOC (single page only)
 PPTX/PPT (single slide only)
 EPS





The legends should be included in the main manuscript text file at the end of the 
document, rather than being a part of the figure file. For each figure, the following 
information should be provided: Figure number (in sequence, using Arabic numerals 
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- i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed legend, up
to 300 words. 
Please note that it is the responsibility of the author(s) to obtain permission 
from the copyright holder to reproduce figures or tables that have previously 
been published elsewhere. 
Preparing a personal cover page 
If you wish to do so, you may submit an image which, in the event of publication, 
will be used to create a cover page for the PDF version of your article. The cover 
page will also display the journal logo, article title and citation details. The image 
may either be a figure from your manuscript or another relevant image. You must 
have permission from the copyright to reproduce the image. Images that do not meet 
our requirements will not be used. 
Images must be 300dpi and 155mm square (1831 x 1831 pixels for a raster image). 
Allowable formats - EPS, PDF (for line drawings), PNG, TIFF (for photographs and 
screen dumps), JPEG, BMP, DOC, PPT, CDX, TGF (ISIS/Draw). 
Preparing tables 
Each table should be numbered and cited in sequence using Arabic numerals (i.e. 
Table 1, 2, 3 etc.). Tables should also have a title (above the table) that summarizes 
the whole table; it should be no longer than 15 words. Detailed legends may then 
follow, but they should be concise. Tables should always be cited in text in 
consecutive numerical order. 
Page 92 of 97 
Smaller tables considered to be integral to the manuscript can be pasted into the end 
of the document text file, in A4 portrait or landscape format. These will be typeset 
and displayed in the final published form of the article. Such tables should be 
formatted using the 'Table object' in a word processing program to ensure that 
columns of data are kept aligned when the file is sent electronically for review; this 
will not always be the case if columns are generated by simply using tabs to separate 
text. Columns and rows of data should be made visibly distinct by ensuring that the 
borders of each cell display as black lines. Commas should not be used to indicate 
numerical values. Color and shading may not be used; parts of the table can be 
highlighted using symbols or bold text, the meaning of which should be explained in 
a table legend. Tables should not be embedded as figures or spreadsheet files. 
Larger datasets or tables too wide for a landscape page can be uploaded separately as 
additional files. Additional files will not be displayed in the final, laid-out PDF of the 
article, but a link will be provided to the files as supplied by the author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet 
(.xls ) or comma separated values (.csv). As with all files, please use the standard file 
extensions. 
Preparing additional files 
Although Pediatric Rheumatology does not restrict the length and quantity of data 
included in an article, we encourage authors to provide datasets, tables, movies, or 
other information as additional files. 
Please note: All Additional files will be published along with the article. Do not 
include files such as patient consent forms, certificates of language editing, or 
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revised versions of the main manuscript document with tracked changes. Such files 
should be sent by email to PRjournal@nationwidechildrens.org, quoting the 
Manuscript ID number. 
Results that would otherwise be indicated as "data not shown" can and should be 
included as additional files. Since many weblinks and URLs rapidly become broken, 
Pediatric Rheumatology requires that supporting data are included as additional files, 
or deposited in a recognized repository. Please do not link to data on a 
personal/departmental website. The maximum file size for additional files is 20 MB 
each, and files will be virus-scanned on submission.  
Additional files can be in any format, and will be downloadable from the final 
published article as supplied by the author. We recommend CSV rather than PDF for 
tabular data. 
Certain supported files formats are recognized and can be displayed to the user in the 
browser. These include most movie formats (for users with the Quicktime plugin), 
mini-websites prepared according to our guidelines, chemical structure files (MOL, 
PDB), geographic data files (KML).  
If additional material is provided, please list the following information in a separate 
section of the manuscript text: 
 File name (e.g. Additional file 1)
 File format including the correct file extension for example .pdf, .xls, .txt,
.pptx (including name and a URL of an appropriate viewer if format is
unusual)
 Title of data
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 Description of data
Additional files should be named "Additional file 1" and so on and should be 
referenced explicitly by file name within the body of the article, e.g. 'An additional 
movie file shows this in more detail [see Additional file 1]'. 
Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and should 
be viewable using free or widely available tools. The following are examples of 
suitable formats. 
 Additional documentation
o PDF (Adode Acrobat)
 Animations
o SWF (Shockwave Flash)
 Movies
o MP4 (MPEG 4)
o MOV (Quicktime)
 Tabular data
o XLS, XLSX (Excel Spreadsheet)
o CSV (Comma separated values)
As with figure files, files should be given the standard file extensions. 
Mini-websites 
Page 95 of 97 
Small self-contained websites can be submitted as additional files, in such a way that 
they will be browsable from within the full text HTML version of the article. In order 
to do this, please follow these instructions: 
1. Create a folder containing a starting file called index.html (or index.htm) in
the root.
2. Put all files necessary for viewing the mini-website within the folder, or sub-
folders.
3. Ensure that all links are relative (ie "images/picture.jpg" rather than
"/images/picture.jpg" or "http://yourdomain.net/images/picture.jpg" or
"C:\Documents and Settings\username\My Documents\mini-
website\images\picture.jpg") and no link is longer than 255 characters.
4. Access the index.html file and browse around the mini-website, to ensure that
the most commonly used browsers (Internet Explorer and Firefox) are able to
view all parts of the mini-website without problems, it is ideal to check this
on a different machine.
5. Compress the folder into a ZIP, check the file size is under 20 MB, ensure
that index.html is in the root of the ZIP, and that the file has .zip extension,
then submit as an additional file with your article.
Style and language 
General 
Currently, Pediatric Rheumatology can only accept manuscripts written in English. 
Spelling should be US English or British English, but not a mixture. 
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There is no explicit limit on the length of articles submitted, but authors are 
encouraged to be concise.  
Pediatric Rheumatology will not edit submitted manuscripts for style or language; 
reviewers may advise rejection of a manuscript if it is compromised by grammatical 
errors. Authors are advised to write clearly and simply, and to have their article 
checked by colleagues before submission. In-house copyediting will be minimal. 
Non-native speakers of English may choose to make use of a copyediting service. 
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For guidance, please 
visit our page on Writing titles and abstracts for scientific articles.  
Tim Albert has produced for BioMed Central a list of tips for writing a scientific 
manuscript. American Scientist also provides a list of resources for science writing. 
For more detailed guidance on preparing a manuscript and writing in English, please 
visit the BioMed Central author academy. 
Abbreviations 
Abbreviations should be used as sparingly as possible. They should be defined when 
first used and a list of abbreviations can be provided following the main manuscript 
text. 
Typography 
 Please use double line spacing.
 Type the text unjustified, without hyphenating words at line breaks.
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 Use hard returns only to end headings and paragraphs, not to rearrange lines.
 Capitalize only the first word, and proper nouns, in the title.
 All pages should be numbered.
 Use the Pediatric Rheumatology reference format.
 Footnotes are not allowed, but endnotes are permitted.
 Please do not format the text in multiple columns.
 Greek and other special characters may be included. If you are unable to
reproduce a particular special character, please type out the name of the
symbol in full. Please ensure that all special characters used are
embedded in the text, otherwise they will be lost during conversion to
PDF.
Units 
SI units should be used throughout (liter and molar are permitted, however). 
